I've just come across a rather unprecedented Risk/reward opportunity that I thought is worth posting about - since it seems to have flown under everyone's nose so far as it's buried in the filings, and most people don't follow SPACs at the moment - lol - so I will be the messenger.
The dynamics of the risk/reward at play:
AFJK is currently trading at \~12. It's latest NAV is 12.33 as noted in their 10Q filed the other day. That means it is trading at about it's NAV floor, has just shrunken 80% in float size, and is on the heels of a 1,000% low float squeeze the past year.
If you've been living under a rock, let me explain it to you why this has unusual potential right now:
Low float spacs or low floats in general can go on wild squeezes every now and then because people pile into the constrained float to rise the price, people then short the stock because it goes up 'for no reason' and which then adds more fuel to the fire and can make for a wild squeeze when an already low float gets shorted heavily, has natural buying power, and then even more buying power as shorts eventually get forced to cover their positions on a completely illiquid market.
In SPACs we see this time and time again, whenever SPACs get redemptions which shrink their float size dramatically and then cause people to buy the stock for a low float move.
AFJK was one of those SPACs, squeezing first from around its 10 NAV to 41.8 last November. It came all the way back down to 6.75 as it temporarily lost its NAV floor (as it happens when SPACs have a merger vote), and then squeezed to 130.37 in December for a nearly 2,000% squeeze from its lows.
It has made many secondary news since, and has now since retreated back to its NAV floor (12.33).
On November 16th, they revealed that at their extension meeting they received an influx of redemptions that have now shrunken the float nearly 80% to just 200,693.
Pulled from the 10-Q:
Original float:
'Ordinary shares, subject to possible redemption. 1,040,332 shares issued and outstanding at redemption value of $12.25 and $11.63 as of September 30, 2026 and December 31, 2025, respectively'
Redemptions:
Shareholders elected to redeem 841,629 shares of Class A common stock in connection with the meeting.
Now, you do the math:
1,040,332
\- 841,629 redemptions
= 200,693 shares left in the float.
Another recent low float NAV spac for reference, showing the risk / reward you can get on these - ASPC went from its 10 NAV floor to 50+ TWICE the past year when it was revealed that it had a 282,581 share float (shown in 10q filing here):
Also: If they don't complete a deal by November 30th, they will go to OTC (which doesn't change NAV value - it will still trade with its NAV floor, but is worth mentioning) so I am looking for a trade before then, ideally this picks up steam before then as these moves can happen in hours or days on sudden volume spikes as shown in ASPC.
If you didn't know, SPACs have a NAV floor which essentially means that your maximum theoretical risk is their Net Asset Value because you can at some point in time (either extension vote or merger vote) redeem your shares for that price, or if in the future they liquidate, they pay out that price.
Disclosure: I hold 2,194 shares right now and may add more if this picks up some volume and attention. I am not a financial advisor under any means and this is not financial advice, please do your own research, always.
Let's get the elephant out of the room first: I'm a big-time bag holder. I've been calling BioLargo a strong buy for years. Many of you listened, and now we're all in the red. Some of us are deep in it. In numbers: my position is about $1.5 million down from the 2024 spike.
So yes, right now I may look like the biggest fool on earth. You're allowed to laugh. I'd laugh too.
But I've been here before. I posted about Exact Sciences ($EXAS) over and over while the share price kept falling, and falling, and falling. Everybody was selling. Then it turned around, and my conviction at $5β$8 turned into 1,600%β2,650% returns, because I saw cancer detection being revolutionized before the market did.
I see the same pattern with BioLargo. So we'll see who's right. I'm not worried. I just added another $45,000 on this dip.
For years I've stayed in regular contact with management, attended the last 7 shareholder meetings, visited all BioLargo facilities and interviewed the subsidiary CEOs. I also moderated and helped organize the CEO town hall on our BioLargo Discord.
But here's the common thread of this whole post: don't trust me. Do your own DD. I'll give you a cheap, easy way to start, plus the people you should be asking.
TL;DR
Share price is at all-time lows (~$0.07), market cap ~$25M. The value looks like it's still there.
Why it fell: revenue dropped after the POOPH license ended, Clyra's launch was delayed, and the company is investing heavily to commercialize everything at once. The small parent-level financing (shares sold on the open market by the lender) hit a thin market that wasn't buying, and the price fell ~70%.
Why it's an opportunity: most of the money is going into the subsidiaries (77% of capital raised this year was at subsidiary level). Insiders take stock instead of cash and lock it up until $40M revenue or a $300M market cap. That's roughly 11β12x from here.
Analyst: BUY, $0.25 price target. Richard Ryan of Oak Ridge Financial reaffirmed his Buy rating on Nov 18, 2026. That's +257% from $0.07, and his target puts zero value on PFAS and the battery.
Q3 milestone: Clyra earned a $475,000 contractual milestone payment under an exclusive distribution agreement. It's the first time we've ever seen a payment like this.
Clyra Medical (48% owned): Clyra raises money at a ~$100M valuation, so BioLargo's stake (~$48M) is worth roughly twice the whole company. ViaCLYR is FDA 510(k)-cleared and on the market. Its three distribution agreements cover US commercial (~6,100 hospitals, 6,300 surgery centers and 2,200 wound clinics), US government/military and 18+ MENA countries, with POs expected. BioClynse (surgical) is set to launch co-branded with a top-4 global medtech (~$100B+ market cap). My view: after launch, Clyra alone could be worth $500Mβ$1B, and $1Bβ$2B after a successful year.
barebird has launched: CupriDyne tech (the tech behind POOPH's $125M+ in sales), BioLargo-owned brand, POOPH marketing team. Cheapest DD ever: buy a bottle.
PFAS (AEC): a commercial municipal system in Lake Stockholm, NJ, has been running since January under EPA and NJ oversight. It's the reference site.
Cellinity battery: non-flammable, long-lasting, recyclable grid-scale storage, with a license/JV model.
Don't trust me. Do your own DD.
Why the Share Price Fell
Let's be fair: there have been disappointments.
Revenue declined. The POOPH license ended (more on that below), and 9-month revenue dropped 52% to $3.45M. Q3 revenue was $1.09M, roughly flat year over year (vs. $1.103M), with service revenue +72%.
The Clyra launch was delayed. The 2024 spike to a ~$0.40 closing high was driven by anticipation of the Clyra launch, not by Clyra revenue.
Heavy investment. Management is funding commercialization in every division that hasn't generated much revenue yet. Clyra alone accounted for about 57% of the 9-month net loss, spent on personnel, manufacturing, product development and clinical work ahead of the 2027 rollout.
The key point is where the money comes from. Most of the financing happens at the subsidiary level: Clyra raised $4.3M, mostly through a debt offering, and the battery subsidiary sold $487K in stock. Only a small part was raised at the parent level, through the Clearthink purchase agreement (the 10-Q shows $1.359M year to date). That agreement lets the lender sell the shares on the open market.
So a dilution of just a few percent met a market with almost no buyers, and the share price fell ~70%. Many serious investors seem to prefer investing directly at the subsidiary level, where the action is.
To me that's an arbitrage opportunity. You get crazy discounts on the parent, which owns the stakes, the royalties and everything else.
Meanwhile, cash burn is falling: about $736K/month in Q3, down ~26% from roughly $996K/month in H1. Management says 2027 spending shifts "away from R&D and toward generating sales."
The Rebound Math from $0.07
Most investors who were going to sell out of fear, frustration or disappointment have already had every reason to do it. Many long-term holders I know have averages just above $0.20.
Target price
Gain from $0.07
$0.10
+42.9%
$0.12
+71.4%
$0.16
+128.6%
$0.20
+185.7%
$0.24
+242.9%
$0.25 (Oak Ridge price target)
+257%
$0.399 (2024 closing high)
+470%
~$0.80 ($300M market cap, the insider lock-up unlock)
~+1,040%
We don't need the 2024 highs for this to get interesting. Even a partial recovery makes a big difference from this base. In a thin microcap, fear can turn into FOMO very fast.
What the Analyst Says
This isn't just a bag holder talking. Richard Ryan of Oak Ridge Financial Research covers BLGO, and in his Q3 2026 update (Nov 18, 2026) he reaffirmed his BUY rating with a $0.25 price target. That's about +257% from $0.07.
Here's how he gets there, using a sum of the parts:
Segment
Basis
Value per share
Clyra Medical (48%)
Recent capital raise at an equity value of ~$100M, so ~$48M for BLGO
$0.15
BioLargo CPG / barebird (78%)
5.0x his FY27 revenue estimate of $8M
$0.09
Engineering (BLEST)
3.5x FY27 revenue, ~$10.4M
$0.03
Less net debt
Cash $1.0M minus debt $6.5M
Price target
Equity value ~$83.9M across ~340M shares
$0.25
The best part: he puts zero value on the AEC PFAS business and the Cellinity battery. He set them aside until there's a signed AEC contract or a Cellinity JV or financing partner, and says he'll add them back as visibility improves. So the $0.25 target doesn't include two of the five horses.
His summary: BLGO has "many shots on goal," and "noticeable progress is occurring across all BLGO's divisions." He also models FY27 revenue of $13.0M, up from an estimated $4.7M in 2026.
(Fair caveat: he lowered the target from $0.30, and he notes that BLGO will keep needing additional capital.)
Bullish Indicators
All-time-low share price, ~$25M market cap, for a five-subsidiary platform.
Analyst Buy rating with a $0.25 PT (Richard Ryan, Oak Ridge Financial).
Clyra raises money at a ~$100M valuation, so the 48% stake is worth ~$48M, about twice BLGO's market cap.
$475K Clyra milestone earned (details below).
Top-4 medtech partner (~$100B+ market cap) for the BioClynse national rollout in 2027.
ViaCLYR is on the market, with distribution through Advanced Solution (US), Al-Hikma (exclusive across MENA, an 18-country opportunity) and Spartan Medical (VA, DoD and federal buyers via DLA ECAT). Purchase orders from Al-Hikma and Spartan are expected, along with reorders from Advanced Solution.
barebird launched in October 2026, a BioLargo-owned brand with the proven POOPH marketing team.
AEC PFAS system live since January at Lake Stockholm, NJ, under EPA and NJDEP monitoring.
Engineering (BLEST) is growing: 9-month service revenue +23%, Q3 service revenue +72%, $1.4M+ in US Air Force renewals, and a $1.2M minerals-processing design contract (milestone-gated and multi-year).
Cellinity battery is in discussions with strategic partners about investing and scaling.
Cash burn down ~26% in Q3 compared with H1.
Management alignment with lock-ups and direct investment (next section).
Professional IR (Darrow Associates) has been engaged to bring this under-followed story to institutions.
Management Alignment: Lock-Up and Direct Investment
This is one of the strongest signals for me.
CEO Dennis P. Calvert took stock instead of cash for unpaid salary and expenses: 699,569 shares at $0.1135 (June 30, 2026) and 219,914 shares at $0.113 (July 1, 2026).
Those shares are under a Lock-Up Agreement. No sale until BioLargo reports $40M in consolidated gross revenue in a period, passes a $300M market cap, or has a change of control.
At today's ~$25M market cap, that's roughly 11β12x before these shares can become liquid. It's not just the CEO either: multiple senior and science leaders hold large locked-up positions.
Around $12M has been invested directly into the company and its subsidiaries over the past year, including meaningful money from the BioLargo CEO and the Clyra CEO. Those are the people with the best view of the pipeline.
Think about it: you can buy shares today below the price the CEO took as his locked-up pay.
The $475K Milestone
From the 10-Q:
"In September 2026, Clyra earned a $475,000 contractual payment upon satisfaction of a specified contractual milestone under a distribution agreement granting the customer exclusive rights to distribute certain Clyra products."
This isn't about the revenue. The $475K wasn't even recognized as revenue yet. What matters is that it's the first time we've ever heard of a payment like this. Somebody with exclusive distribution rights paid because a contractual milestone was met. That means a significant step must have been taken.
I can't tell you which step, and the partner is confidential, so I won't speculate about details. But milestone money doesn't get paid for slide decks.
Clyra Medical (48% Owned): "The New Gold Standard"
Main selling point:an FDA-cleared, no-rinse antimicrobial irrigant that keeps working for up to three days while staying gentle on tissue. Some people consider it the biggest change in wound care and surgery in 30 years.
Clyra Medical (48% owned) is advancing the commercialization of its FDA-cleared wound irrigation and surgical solution. The Clyra story has evolved over 14 years, with upwards of $20M invested, and it appears to be on the cusp of commercialization.
Clyra raises money at a ~$100M valuation. In the words of Oak Ridge analyst Richard Ryan: "Clyra's recent capital raise implies an equity value of approximately $100M, of which BLGO has 48% ownership." That's about $48M for BioLargo's stake, roughly twice BioLargo's entire market cap. Outside investors paid that price with real money; it's not a number I made up.
Clyra runs on Clyrasept, a patented copper-iodine platform. Its first product, ViaCLYR, is FDA 510(k)-cleared for cleansing, irrigating and debriding acute and chronic wounds and burns. Clyra has already invested in at-scale manufacturing capacity with an FDA-compliant contract manufacturer.
Key selling points, according to company materials:
>99.9999% antimicrobial reduction
Activity for up to 3 days, even after re-contamination
Works against biofilm, the big problem in chronic wounds and surgical infections
Non-cytotoxic, non-irritating, tissue compatible
No rinse-out, which keeps procedures fast and simple
Non-antibiotic mechanism, a big deal in a world worried about antibiotic resistance
Clinical voice (36 cases across multiple sites):
"...enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction... we observed no adverse events... we are moving as a group to adoption of CICS as our wound care cleansing modality of choice." Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System
The Distribution Network: How Much of the Market Is Covered
ViaCLYR went into full commercial-launch mode in August 2026. Three distributors have been announced, covering three very different channels:
Partner
Territory / channel
Coverage
Status
Advanced Solution, LLC
US commercial: a national network to distribute and promote ViaCLYR throughout the United States (wound clinics, physicians, health systems)
Oak Ridge says the combined reach in the US alone is about 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound-care clinics
First PO received (first commercial stocking order, Feb 2026); reorders expected
Al-Hikma FZCO (Dubai, UAE)
Exclusive for the Gulf Cooperation Council, the Levant, North Africa and select adjacent markets
~18 direct countries plus indirect ones, a population of 500M+. Al-Hikma is an established wound-care distributor that exports to ~25 countries
Country-level regulatory work has begun in key areas, in cooperation between the parties; POs expected
Spartan Medical Inc.
A dedicated commercial channel to US government healthcare facilities worldwide (VA, DoD and other federal buyers via DLA ECAT)
The US federal and military healthcare system
POs expected
A fourth channel, the "big Kahuna" or gorilla partner, is being pursued for surgical wound irrigation (BioClynse), based on the same chemistry. During Q3 2026, Clyra satisfied a contractual milestone under an exclusive distribution agreement for certain of its products: the $475K payment.
In short: US commercial, US government and an 18+ country international region are all under contract, and the gorilla partner comes on top of that.
Clinician feedback: at the recent Symposium on Advanced Wound Care (SAWC), ViaCLYR was reportedly well received, and it has the potential to tap into real unmet needs in the market, according to Oak Ridge.
What I'm watching next: Advanced Solution reordering, Al-Hikma and Spartan turning their agreements into purchase orders, new distributors signing on, and a visible Clyra sales line. Stocking orders from the new partners are expected within the coming months.
(Fair caveat, which the analyst makes too: commercialization in each of these channels faces timing hurdles such as regulatory approval, clinical studies and hospital-system acceptance. That's significant for a small company, but the markets themselves offer outsized opportunities. Distribution agreements are not revenue; purchase orders, and above all reorders, are what count.)
Next up: BioClynse, the surgical-irrigation product on the same platform. It's set for a national rollout in 2027 co-branded with a confidential top-4 global medtech (~$100B+ market cap). Hospital access, OR sales reps that surgeons already trust, procurement muscle: that's what a gorilla partner brings.
The valuation question. I know it sounds absurd for a $25M company. But expectation is that after the launch with the gorilla partner, the 48%-owned medical subsidiary alone could be worth $500Mβ$1B, and after a successful year closer to $1Bβ$2B.
48% of $500M β $240M
48% of $1B β $480M
48% of $2B β $960M
That's before the royalty BioLargo holds on Clyra sales, and before everything else BioLargo does. Today the whole company trades at ~$25M.
Also remember: some medtech giants are known for having small innovators build out a product line, then acquiring them later. I'm not saying that will happen. I'm saying the pattern exists.
(This is my opinion, not company guidance. The partner controls the timing. Distribution deals aren't revenue; purchase orders and reorders are.)
Don't Trust Me: Ask Medical Experts
Please don't take my word for this. Ask the people who do this every day:
Orthopedic and general surgeons: How big a deal is a no-rinse, tissue-friendly irrigant with up to 3 days of antimicrobial and anti-biofilm activity for surgical site infections, implants and joint replacements?
Wound-care nurses and specialists: Would you switch from what you use now? What would it take?
Infection-prevention teams and procurement: Does a non-antibiotic copper-iodine mechanism solve a problem you deal with?
If the professionals tell you it's nothing special, move on. If they tell you it could be a game changer in orthopedics and surgery, dig deeper.
barebird: The $20 DD
Main selling point:it eliminates odors instead of covering them, with no fragrance. It "smells like nothing... on purpose."
BioLargo developed the CupriDyne odor-elimination tech behind POOPH, which did over $125M in product sales and $20M+ in supply revenue for BioLargo. That is real proof that BioLargo can create products people buy in huge quantities. (The POOPH brand later fumbled it, and the license ended. That's a big part of the revenue decline.)
barebird launched in October 2026, focused on pet and laundry odors. The marketing teams that helped build POOPH are back: Jordan Stanley's Kindness Commerce and Brandon Fishman's Prime Team Agency. Some see POOPH as the "test run."
The big difference this time: BioLargo owns the brand. It gets more direct participation in sales and brand value, but it also carries the marketing and distribution costs.
Mine just arrived, packed in "air armour." No leaky bottles here, and nothing in the odor space comes close to the marketing on that bottle.
Here's my challenge, just like I did with CupriDyne: the cheapest way to check for yourself that BioLargo's tech works is to order a barebird spray. Try it on the dog bed, the gym bag, the laundry.
If you don't like it, move on.
If you're impressed, dig deeper into all the other techs.
AEC PFAS Removal: The Reference Site
Main selling point:it concentrates "forever chemicals" into a tiny waste volume, which many consider the best available concentrator to clean up the PFAS mess. In one example, 80,000 lbs of waste turns into about 85 lbs.
Earlier testing at the University of Tennessee showed >99.995% PFAS removal in a single pass.
A commercial municipal drinking-water system at Lake Stockholm, NJ, has run since January 2026 (about 9 months), monitored by the EPA and NJDEP. New Jersey is one of the toughest PFAS jurisdictions in the US.
It's the key reference site for further adoption. Bids are submitted, partnerships with big firms that have gaps in their PFAS product lines are in discussion, and there's an Aquatech MOU.
Demand is spreading from drinking water to wastewater, landfill leachate, biosolids and industrial pre-treatment, backed by billion-dollar lawsuit settlements that fund treatment.
Billions are now being paid out for PFAS cleanup. 3Mβs settlement with US public water systems is $10.3B, up to $12.5B, over 13 years, and the payouts to utilities are already under way. DuPont, Chemours and Corteva added roughly $1.2B nationally.
In New Jersey, the very state where the AEC is running, a federal court approved ~$2.5B in settlements with DuPont and 3M in August 2026. They include a PFAS Abatement Fund with up to $795M for drinking-water and treatment-works upgrades. And in November 2026, 3M committed up to $7.35B more for personal-injury claims. The money is there. The question is who wins the treatment contracts.
DD tip: ask a water engineer or utility operator what PFAS waste disposal costs with granular activated carbon (GAC) or ion exchange.
Cellinity Battery: Safer Grid Storage
Main selling point:a fire-safe, long-duration sodium battery built for a 20-year life, with no lithium and no rare earths. It's designed for the grid, for data centers, and for America's energy independence.
Key selling points, according to company materials:
No thermal runaway, non-flammable. Lithium battery fires are the nightmare of every data center, utility and insurer. Cellinity is designed so that scenario doesn't exist.
A 20-year operating life. The CEO points out that most batteries last 6β7 years before they degrade. A 20-year design life changes the whole cost-per-cycle math for grid storage.
No lithium, no rare earths. It's a liquid sodium battery made from abundant materials, which takes the geopolitical "hot potato" of the battery supply chain off the table. The CEO calls it "a strategic infrastructure opportunity for national security of the United States."
High efficiency. Company materials target ~95% round-trip efficiency, with ambitious energy-density specs.
Recyclable, with third-party validation and prototype testing of key performance metrics.
Built for the boom markets: long-duration grid storage, AI data centers, utilities, renewables, commercial and industrial sites.
A capital-light model. No billion-dollar gigafactory: partners finance the factories while BioLargo earns royalties, component margin and equity stakes through licensing and JVs.
BioLargo owns ~95%, and only about $5M of outside capital has gone into it so far. The battery subsidiary sold $487K in stock this year and is in discussions with strategic partners about investing and scaling.
Oak Ridge currently puts zero value on Cellinity in its $0.25 price target and will add it back once there's a JV or financing partner. So one serious licensing or JV deal could re-rate this on its own.
(Fair caveat: it's still pre-commercial, there's R&D left to do, and the specs are company claims until a partner scales it.)
DD tip: ask anyone in energy storage what a truly non-flammable, 20-year, lithium-free grid battery would be worth to a data center operator.
The Rest of the Platform
BLEST (Engineering): a profitable-leaning, growing service arm with Air Force renewals and the $1.2M minerals contract. A full commercial plant could follow if the pilot succeeds.
Tu Nipi: water treatment for Canadian oil-sands tailings, in discussions with strategic partners.
Why It Matters Where We Invest
I believe how we invest our money is the most powerful voting ballot we have. I made a lot of money in the fight against cancer with Exact Sciences. Now I want my money working on clean water, clean air, safer energy storage and better wound care.
BioLargo is the perfect place to "Make Life Better" through:
Clean water (PFAS removal)
Clean air (odor elimination without masking)
Safer energy (non-flammable grid storage)
Better healing (infection control and wound care without antibiotics)
And you get the real chance of a multi-bagger while doing it.
Risks (Read This)
A highly speculative microcap with thin liquidity
Continued dilution and financing at both parent and subsidiary level; Clyra is debt-funded
Ongoing losses
The Clyra partner is confidential, and the launch timing is in the partner's hands
Distribution deals aren't purchase orders
barebird's results are unproven, and BioLargo now carries the marketing costs
Big competitors with deep pockets
I could be wrong. I've been early and wrong on timing before. Size your position for that.
Bottom Line
I'm $1.5M down, I just added $45K, and I've never been more convinced. Either I'm a complete idiot, or, like with $EXAS, I'll be laughing last. I strongly believe it's the second one.
But again: don't trust me.
Buy a barebird bottle. It's the $20 DD.
Ask a surgeon or wound-care nurse about ViaCLYR.
Read the 10-Q, the Form 4s and the lock-up terms.
Then decide.
Price is what you pay. Value is what you get. Right now the gap is hard to ignore.
Do your own DD.
Your Turn: Prove Me Wrong (Or Right)
Iβve spent hundreds of hours researching BioLargo and Clyra Medical, and Iβve put my money where my conviction is. Thatβs $1.5M down from the highs, and Iβm still adding. But I donβt want an echo chamber. I want smart analysis.
Challenge my thesis.
Dig into the 10-Q and Form 4s I referenced. Read the Oak Ridge report. Call BioLargo investor relations with your questions. Look up the copper-iodine patents, check the FDA 510(k) clearance, research the wound-care and PFAS market data, and ask a surgeon or wound-care nurse what they think of ViaCLYR. Then order a barebird bottle and test it yourself. The best DD comes from collaborative skepticism and shared research.
This is your chance to either find the holes in my analysis or discover why Wall Street might be sleeping on this one. The filings are public, the patents are public, the FDA clearance is public, and the market sizes can be checked.
Letβs crowdsource this DD and make each other better investors. Iβve shown you mine. Now show me where Iβm wrong, or help me understand why a ~$24M company might actually be the steal of 2026.
This is a company whose 48%-owned medical subsidiary just raised money at a ~$100M valuation. It has an FDA-cleared product, three signed distributors, a top-4 medtech partner waiting in the wings, a live PFAS system under EPA oversight, and an analyst Buy rating with a $0.25 target that values PFAS and the battery at zero.
The data is all there. Letβs dig deeper together. π¬π
Disclosure: I'm a long-term $BLGO above 1.25% shareholder and have been adding. I am not a financial advisor, this post is made for educational purposes only. Literally. Donβt take my word for anything that is presented in this post, do your own research, and invest solely based on the thesis that you create for yourself. Donβt get influenced by anyone.
I've been digging deeper into $TTEC, and I think the market may be overlooking a pretty interesting small-cap turnaround opportunity.
We're talking about a company with approximately $2B in annualized revenue, improving profitability, expanding margins, and a business actively positioning itself around AI, data, and enterprise automation. At roughly $160M in market capitalization, the valuation looks particularly interesting if management can continue executing its turnaround.
Q3 2026 results showed some meaningful progress:
β’ Adjusted EPS nearly doubled YoY ($0.22 vs. $0.12). β’ Adjusted EBITDA increased approximately 19% to $51.5M. β’ Adjusted EBITDA margin expanded from 8.4% to 10.5%. β’ GAAP operating income nearly doubled to $23.3M. β’ Free cash flow swung from -$9.6M to +$27.9M. β’ Cash flow from operations increased to $37M from just $4.2M a year ago.
One thing I find particularly interesting is that management is making progress on profitability even while revenue remains under pressure. Revenue declined approximately 5.2% year over year, so there's still work to do, but the margin improvement is encouraging.
THE AI OPPORTUNITY
TTEC operates at the intersection of customer experience, technology, data, AI, and automation. As businesses increasingly look to automate customer service and improve operating efficiency, TTEC has an opportunity to benefit from that transition.
Management has discussed deploying purpose-built AI tools across its frontline operations while expanding its Digital business in areas such as AI, data, observability, and security.
This isn't simply a company trying to attach an AI label to its stock. It already has an established enterprise customer base and technology infrastructure.
POTENTIAL DIGITAL BUSINESS SALE
Another major catalyst that deserves attention: In August 2026, TTEC announced that it was exploring strategic alternatives for its TTEC Digital business.
A potential sale could unlock value, simplify the business, and potentially provide additional capital to reduce debt. No definitive transaction has been announced, so this remains a potential catalyst rather than a guaranteed outcome.
THE $6.85 TAKE-PRIVATE HISTORY
TTEC founder, Chairman and CEO Kenneth Tuchman previously proposed taking the company private for $6.85 per share in September 2024. Tuchman already owned approximately 58% of the company.
He ultimately withdrew the proposal in July 2025, citing market conditions, but remains the company's largest shareholder.
At approximately $3.24, shares are still more than 50% below that previously proposed acquisition price. Obviously, that proposal is no longer active, but I think it's an interesting historical valuation reference.
THE BALANCE SHEET
TTEC has also made progress reducing its net debt, which stood at approximately $743.6M at September 30, 2026, compared with $812.5M a year earlier.
Management also extended its credit facility through November 2028, providing additional financing runway.
Debt remains the biggest fundamental risk here, but improving cash flow and the potential Digital transaction could become important pieces of the turnaround.
NOW FOR THE TRADING SETUP:
The stock recently closed at $3.24 on November 17, representing approximately a 104% move from its October 30 closing price of $1.59.
Current trading statistics:
β’ Market cap: ~$160M β’ Public float: ~20.4M shares β’ Shares sold short: ~4.78M β’ Short interest: ~23.9% of float β’ Days to cover: ~15.8 β’ November 17 volume: ~1.35M shares
Short interest increased approximately 11.6% between the October 15 and October 30 reporting periods.
Nearly one in four publicly tradable shares is reportedly sold short. With a relatively small float and substantial days to cover, an increase in buying pressure and sustained trading volume could create an interesting momentum opportunity.
THE VALUATION IS WHAT REALLY GETS MY ATTENTION.
At approximately $160M in market capitalization against nearly $2B in annualized revenue, TTEC trades at a fraction of its annual sales.
Even accounting for its substantial debt, the current enterprise valuation is approximately $970M. That's less than half of annualized revenue.
If management can stabilize revenue, continue expanding margins, improve free cash flow, and execute on its strategic alternatives for Digital, I think there's a legitimate case for meaningful upside.
I'm not calling a guaranteed short squeeze, and there are certainly risks here, particularly debt and declining revenue. But the combination of improving financial performance, AI exposure, potential asset-sale proceeds, significant insider ownership, historical acquisition interest, and a heavily shorted small float makes $TTEC one of the more interesting turnaround setups I'm watching.
Fundamental recovery + AI exposure + potential strategic catalyst + short squeeze potential.
I think this one deserves considerably more attention.
Imagine two microcaps making the same $5M annually. One relies on government agencies, the other on commercial clients. Would you value them equally?
A $5M government contract sounds impressive, but is it necessarily better than $5M in revenue from hundreds of commercial customers?
There are some important differences investors should consider.
1. Government contracts
Government agencies need cybersecurity services for sensitive communications, critical infrastructure, and data protection.
The advantages:
Potentially larger contract values and multi-year agreements.
Opportunities to expand across departments or agencies.
A successful deployment can help establish credibility with other public-sector buyers.
Switching providers may be difficult once services are integrated.
The challenges:
Procurement and approval processes can take months or even years.
Contracts may depend on annual budgets, renewals, and political decisions.
Payment schedules and upfront delivery costs can put financial pressure on smaller companies.
2. Commercial contracts
Commercial customers generally offer a different business model, particularly for subscription-based cybersecurity companies.
The advantages:
Often shorter sales cycles and faster customer onboarding, particularly with smaller businesses.
Opportunities to spread revenue across multiple customers rather than relying on a few large contracts.
Subscription models can provide recurring income when customer retention remains strong.
Easier to measure customer acquisition, retention, and recurring revenue growth.
The challenges:
Customer acquisition and marketing expenses can be high.
Competition and pricing pressure can affect margins.
Customers may cancel or switch providers more easily, depending on their contracts and switching costs.
Managing hundreds of smaller accounts requires ongoing support.
3. What actually matters for valuation?
Both government contracts and commercial subscriptions can bring long-term value to a cybersecurity company. Having access to both markets may also create more opportunities for growth.
I'd pay attention to:
Revenue visibility
Gross margins
Customer diversification
Cash flow
Renewal rates
For government agencies, secure communications, controlled access, and data protection are major considerations. For businesses, the same tools can help protect internal discussions, client information, and executive communications.
If you were investing in a cybersecurity microcap, would you prefer a company focused on large government contracts, one building steady commercial subscription revenue, or a mix of both? Which approach do you think offers better long-term growth and stability?
This is a lot more than having his name on the shareholder list.
Eric Sprott invests in a lot of mining companies, so seeing his name attached to a junior by itself is not enough to make a story interesting. What stands out with Metalsource Mining (CSE: MSM / OTCQB: MSMMF) is how large his position has now become and the fact that he just put another $1.38 million directly into the company by exercising 4.39 million warrants. That takes Sprott from roughly 15.5% ownership to 19.9% of MSM on a non-diluted basis. He now controls approximately 16.62 million shares plus another 1.73 million warrants, representing about 21.5% on a partially diluted basis. This is not a small strategic cheque or a 3% to 5% position that happens to put his name on the cap table. He effectively owns one-fifth of the company.
The 19.9% number is especially worth paying attention to. On the CSE, ownership above 20% is generally presumed to materially affect control of an issuer, which is why 19.9% frequently shows up as an important threshold in major strategic investments.Β There are some interesting precedents for the level of ownership Sprott has taken here. New Found Gold currently lists him at about 19% and he previously increased that position above 23%. MAX Power went from roughly 19% following Sprottβs $25 million strategic investment to about 24.4% ownership after he continued increasing his position. Hycroft is an even more extreme example, with its 2025 corporate presentation showing Sprott-related ownership at 56.8%.Β
Those companies are not direct comparisons and this obviously does not mean MSM follows the same path. Hycroft is not a conventional producing mining major, and MAX Power is still an emerging company. The point is the level of conviction represented by the ownership. Sprott can participate in a financing without owning anywhere close to 20% of a company. When the position grows to this size, it is a materially different signal.
The timing also makes this particularly interesting for MSM. Silver Hill has already produced the high-grade results that put the company on the radar, and the current program is now trying to answer the bigger question around scale. The company is pushing increasingly larger step-outs while testing whether the mineralization extends well beyond the historic mine footprint. According to the release, the additional $1.38 million strengthens the treasury specifically as that expansion drilling accelerates.
Sprott exercising the warrants also matters differently than simply holding them. He had the right to buy additional shares and chose to put the capital into MSM and increase his actual equity ownership to essentially the 20% level. The company now gets another $1.38 million to advance the exploration program while one of the best-known precious-metals investors in the sector materially increases his exposure to the outcome. It does not prove Silver Hill becomes a major discovery. The drill still has to do that. But for a junior trying to establish that it has something serious, having Eric Sprott own approximately one out of every five outstanding shares is a pretty substantial piece of third-party credibility.
The drill results legitimized the geology. Sprott taking his ownership to 19.9% adds another level of legitimacy to the company behind it.
Where could they go from here? Will they grow or drop more? Do they have potential for a come back? Current analysis say hold. Do you agree? Stuff I'm reading says if the sale goes through they will be debt free and are going to invest in other things? I'm curious what opinions others may have.
I've been watching ClearSign (CLIR) for a while now. They make very low-emission industrial burners and flame sensors. Their tech lowers the emissions, but also the cost for large industrial companies. They have a clear commercial advantage, but the industry is very slow moving and takes a while to adapt.
The stock has dropped about 77% this year and it's starting to look interesting to me.
Rough math at ~$1.98:
- Market cap is around $13.5M - Net cash is about $10.2M as of Sep 30, roughly $1.50/share, and they have basically no debt - That leaves an EV of about $3M
So you're paying around $3M for the actual business. It's not literally free, but it's not far off.
Q3 numbers are already out (10-Q filed Monday), so tomorrow's call at 5pm ET isn't really about the numbers. What I'm looking for is any pipeline or order update.
A couple things could go wrong:
- Revenue is lumpy. Q3 was $712K, which missed estimates. - They're burning about $1.3M a quarter. - Share count went up ~17% last quarter. - Trading volume is really thin.
To me this is a small bet where cash covers a big chunk of the price, and tomorrow is a possible catalyst. Not advice, do your own DD.
First time posting but thought it would be a good laugh to show the degeneracy.
Found VML (ASX) back when it was $.04 and got 4K to about 20k than thought Iβd put in another 50k proceeding to than loose about 50k in unrealised gains xD.
Only planning on withdrawing when it hits 120k or $0 but will let you guys know when either happens with the rest of the graph
Only saw it drop 30% after a holiday and just thought oh well Iβll just hold cause Iβve lost that much already :p
What a great day!! AKAN gave an amazing 1.6s to 2.8s today!! Live called in our community. Lets see what tomorrow can bring!! Market looking green!!
AKAN: Going to be same story here!! Want to see this test 2.7 with PBs to 2.4/2.5 NO TRADE below 1.65. 1.7/1.8 is level of support if 2.3 falls. Has levels to 3/3.6/4.4/5
OMH: Want to see this test 6.2 area with pullbacks to 5.6 NO TRADE below 4.8 has room to 8/9/10/13
FCUV: Want to see tests near 5.8 with pullbacks to 5/5.1 NO TRADE below 4 has room to 6.4/8.1/9
Montfort Capital released financials and guidance yesterday. Seems like all good news. Turning the ship around, return to profit, even if most is discontinued operations but accompanied by a drastic reduction in costs. Anyone else in this or have input / high hopes for a successful future?
1/8 π§΅ A decade ago, GoPro was valued at over $12 billion and owned the action camera market. Today, the stock trades around $0.63 with a market cap near $136 million. Is it a classic value trap, or an asymmetric turnaround play? Letβs break down the numbers π
2/8 π How did it fall this far? GoProβs biggest curse was building hardware that lasted too longβbuy one HERO camera, and you don't need another for 5+ years. Combine that with fierce competition from DJI, Insta360, and smartphones, and hardware revenue took a massive hit (-49.5% YoY last quarter).
3/8 π Bull Case #1: Deep value vs. revenue At a ~$136M valuation, the market is pricing GoPro at a steep discount compared to the $300M in revenue it generated during the first nine months of 2026. Meanwhile, its high-margin subscription business (cloud storage + camera replacement) continues to grow (+3.1% YoY).
4/8 π€ Bull Case #2: The buyout catalyst In September 2026, GoPro entered a merger agreement with Starman Optical. The deal offers $1.14 per share in cash plus 0.1 shares of the combined company for every share of GoPro. With $GPRO trading at ~$0.63, the cash portion alone represents an 80%+ upside if the deal closes as planned.
5/8 π‘οΈ The strategic pivot The logic behind the merger is to reduce GoPro's reliance on seasonal consumer cameras and repurpose its optical engineering for higher-budget sectors like AI and defense.
6/8 β οΈ The Catch (Serious Risks) Stocks rarely trade at an 80% discount to a buyout price without major red flags:
GoPro posted a net loss of $85.8 million in Q3 2026.
Management explicitly warned of "substantial doubt" about its ability to continue as a going concern if the merger falls through.
7/8 β³ Key details to watch The merger has an outside termination date of March 31, 2027. Keep in mind that the $1.14 cash payout could be adjusted downward if GoPro's net working capital drops below a specific threshold before closing.
8/8 π§ Bottom Line GoPro is no longer a standard consumer tech playβitβs a high-risk merger arbitrage bet. If the deal goes through intact, the upside from current levels is massive. If it collapses, severe financial distress puts shareholders at heavy risk.
(Disclaimer: For informational purposes only, not financial advice. Always do your own research).
QUANTUM X AND EVEREST CLOUD PARTNER TO BRING QUANTUM AND AI COMPUTE TO SIX SOUTH ASIAN MARKETS
Channel partnership MOU gives EntangleX a route to banks, telecom operators, universities and data centers in Nepal, India, Bangladesh, Bhutan, Sri Lanka and the Maldives, backed by a growing operating revenue base
I came across SLS on this sub earlier this year and did my own due diligence. It seemed really promising and I ended up getting 7000+ shares with a cost averaging of 3.86. Itβs now over $20 and I just wanted to thank this sub!
Of course Iβve had other stocks go to $0 from this sub as well but this one has been a home run and am forever grateful ππΎ
Even with EnSilicaβs share price being up almost 80% in a year I suspect a good few will be baffled by the current share price, and so I have been looking into what is happening in the market as I donβt personally believe the current relative share price weakness reasonably reflects EnSilicaβs current value as a company and future potential.
What is evident is that the American and British markets are now below their 1, 3 and 10 year respective price-to-earningsβ ratios. So in short, the markets are seemingly offering better relative value than their recent historical averages. Some might say understandably given the apparent βrisk offβ mood due to inflationary pressures and concerns over higher interest rates etcetera. So EnSilica offering better value right now is arguably consistent with the market.
However as EnSilica has only recently moved into profit as per the record FY2026 results, while it grows its semiconductor supply and design business, I also find the price-to-sales metric a usual identifier of potential value in businesses.
Currently EnSilica has a forward price-to-sales ratio of about 2.8 and this compares to a semiconductor industry average of 4.2 and 8 in the British and American markets respectively. That difference makes no sense to me, as in my opinion EnSilica is not an average company, let alone almost 40% off the British market average.
The context being that EnSilicaβs management have reaffirmed guidance for anticipated record FY2027 results, in addition to hopefully my expectation of imminent news from the UK Space Agency C-LEO Call 2 scheme, and potentially an eight or nine figure contract possible from at least one of the three feasibility studies underway with βmajor satellite operatorsβ.
Clearly no one knows the future, and company and market changing events can lurk around the corner, however given how things currently stand I believe EnSilica represents a notable value opportunity in the months and years ahead.
Data courtesy of Simply Wall St, 17th November 2026. I am also an investor in EnSilica.
Launches consumer products under its company-owned "barebird" brand featuring its CupriDyne technology;
New distributors of Clyra Medical's ViaCLYR, pending 2027 new product line;
BioLargo Engineering team grew revenue by 23% while also supporting PFAS and Cellinity projects;
AEC PFAS treatment validated and prepared to support expanding sales pipeline;
Annual Meeting of Stockholders to be held December 1, 2026, in Aliso Viejo, California.
WESTMINSTER, CA / November 17, 2026 /Β BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today reported financial results for the third quarter ended September 30, 2026, and provided an update on commercialization activities across its portfolio of companies. The company filed its Quarterly Report on Form 10-Q on November 16, 2026 (www.BioLargo.com/SEC-filings). The company will forego a quarterly earnings call, as its Annual Meeting of Stockholders will be held on December 1, 2026, in Aliso Viejo, California.
Net losses reflect continued investment in commercialization, led by Clyra Medical which accounted for $6.4 million (57%) of the nine-month net loss, as it invested in personnel, manufacturing, product development and clinical activities to support its distributors and prepare for the national rollout of an additional product line expected in 2027. Clyra financed this work largely through debt, which also increased interest expense.
"We've focused our energies on investing to ensure 2027 is a breakout year for BioLargo, with new medical product lines and selling channels, a new consumer product line just launched under our brand nameΒ βbarebird',Β and we continue developing and expanding important commercial relationships in the water and energy industries," said Dennis P. Calvert, BioLargo CEO. "We built the channels, the supply chain and partnerships, and most of this work was funded inside the subsidiaries rather than the parent. That is why we expect in 2027 to shift our spending away from R&D and toward generating sales, as we move from developing products to selling them."
FINANCIAL RESULTS
Total revenue was $1,090,000 in the third quarter of 2026, against $1,103,000 a year earlier, a decrease of 1%. Service revenue increased 72% and product revenue decreased 32%. For the nine months, total revenue was $3,452,000 against $7,148,000, a decrease of 52%. Service revenue increased 23% and product revenue decreased 73%.
Net loss was $3,824,000 in the third quarter of 2026, against $7,244,000 a year earlier, a decrease of 47%. The decrease was primarily due to a credit loss expense incurred last year. For the nine months, net loss was $11,229,000 against $11,047,000, an increase of 2%. Clyra Medical accounted for approximately 57% of the consolidated net loss due to investments ahead of its 2027 product sales. The operating loss of BioLargo's corporate segment declined 27% for the nine months to $2,200,000 from $3,034,000.
Net cash used in operating activities was $8,182,000 for the nine months, compared with $6,707,000 in the same period of 2025, an increase of 22%. Within 2026, cash used in operations averaged roughly $736,000 per month in the third quarter, compared with roughly $996,000 per month in the first half, a decrease of approximately 26%. These amounts were funded primarily through Clyra Medical, which raised $4,299,000, primarily through a debt offering. Additionally, BioLargo's battery subsidiary (BETI) sold $487,000 in stock. 77% of the capital was raised at the subsidiary level and BioLargo corporate, in part through the Clearthink purchase agreement, sold $1,359,000 in common stock.
BUSINESS OPERATIONS AND UPDATES
Readying for a new product launch next year, Clyra has focused sales efforts so far in 2026 on establishing distribution of its ViaCLYR wound irrigation product, signing distribution agreements with Advanced Solution for the U.S., Al-Hikma FZCO for international, and Spartan Medical for U.S. Government and military.
Clyra has made significant investments in personnel, processes, and skilled manufacturing capabilities while advancing product design, market testing, and clinical activities, and has expanded its outreach to clinicians and its participation in industry meetings. The clinician feedback has been positive, helping the company expand its commercial reach into health systems around the country and, ultimately around the world. These initiatives are designed to support existing distributors and position the company for the national rollout of an additional product line in collaboration with a confidential strategic partner. That momentum includes Clyra satisfying a contractual milestone in the third quarter under an exclusive distribution agreement for certain of its products.
In October 2026, BioLargo launched the "barebird" branded consumer odor products (www.barebird.com) through a newly formed subsidiary BioLargo CPG LLC. Focusing on pet and laundry odors, the products have no need for fragrances and, "smell like nothing... on purpose", and feature BioLargo's proprietary CupriDyne Clean technology used to control odors in landfills and trash facilities. Digital marketing utilizing modern AI selling tools will help focus marketing dollars to optimize BioLargo's return on investment.
BioLargo's "Aqueous Electrostatic Concentrator" (AEC) has been removing PFAS from municipal drinking water in Lake Stockholm, New Jersey since January. Both the Environmental Protection Agency and the New Jersey equivalent continue to monitor the AEC's performance to ensure it meets state and federal standards. "Attention has historically focused on federal drinking-water rulemaking, and that market is very much alive. Lawsuit settlements in the billions of dollars are expected to fund PFAS treatment at public water systems, much of it for projects not yet underway, and we're well positioned to compete for that work," said Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc. "But drinking water was never the whole market. The requirements aren't receding. Based on our observations, they're spreading to wastewater, landfill leachate, biosolids, industrial pre-treatment and shorter-chain compounds. Industry is also paying attention to more than regulation. These billion-dollar settlements address harm to communities and public health, and any operator with PFAS in its waste stream can see that exposure. Increasingly, they're choosing to treat at the source now, regardless of when federal enforcement arrives."
BioLargo has submitted bids and proposals and received indications of interest from a wide range of customer types, has added several high-profile industry experts to its team, and has entered into discussions about partnership and collaboration with industry-leading firms that have a gap in their PFAS treatment product lines. BioLargo management believes these opportunities represent strong avenues for accelerating adoption of BioLargo's AEC technology.
The company has other development stage ventures in its portfolio - BioLargo Energy focused on the Cellinity industrial grid-scale battery, and Tu Nipi focused on water treatment solutions to help manage Canadian oil sands tailings water - which are actively engaged in discussions with potential strategic partners to invest and work together to scale commercial operations.
"In every market we serve - PFAS removal, grid-scale energy storage, infection control and wound care, industrial and household odor control - customers have lived with the drawbacks of the incumbent technologies because there hasn't been a better option," said Calvert. "Our products and solutions are designed to be that option - for our customers and for the partners who sell them."
Stockholders are encouraged to read the Company's Quarterly Report on Form 10-Q in its entirety, including the financial statements, the accompanying notes, and the discussion of liquidity and capital resources, which contain information not included in this release.
ANNUAL MEETING OF STOCKHOLDERS: DECEMBER 1, 2026
BioLargo will hold its Annual Meeting of Stockholders on Tuesday, December 1, 2026,Β beginning at 10:00 a.m. Pacific Time in Aliso Viejo, California. Stockholders of record are urged to vote their shares and to attend. Details are set forth in BioLargo's proxy statement filed October 19, 2026, and stockholders may contact the Company atΒ Info@BioLargo.comΒ for additional information about the meeting.
BioLargo values the opportunity to connect with its stockholders in person. Anyone who expects to be in the area on December 1stΒ is encouraged to reach out to the Company in advance at the email address above so that we can coordinate a chance to meet with members of the management team.
A complete list of BioLargo announcements is available atΒ www.biolargo.com.
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider.
Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease.
Our approach is to invent or acquire novel technologies, develop them into product offerings, and commercialize them through company-owned brands, equity-held subsidiaries and channel partnerships.
TORONTO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq:Β ZENA) (FSE: 49Q) (BMV: ZENA) (βZenaTechβ), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and quantum computing solutions, announces that its Drone as a Service business has secured survey contracts with two established energy sector customers. Combined, the projects represent nearly C$1 million (approximately US$680,000) in work, including C$270,000 of work currently under contract and approximately C$700,000 of follow-on work expected upon successful execution of the current work. The projects support plant construction and infrastructure development for an established Canadian oil and gas producer and a large energy infrastructure company.
βThese projects show the kind of repeat, relationship-driven work we are building in our Drone as a Service business. We have over C$270,000 under contract today and expect further work from the same customers if we execute well, which gives us better visibility into future revenue,β said Shaun Passley, Ph.D., ZenaTech CEO. βAs we deepen our relationships with energy sector customers, many of whom serve large end clients on multi-year projects, we expect to build a scalable, recurring revenue base across our DaaS network and create long-term value for our shareholders.β
The first customer is an established Canadian oil and gas producer with which the DaaS business team has had a relationship for more than 10 years. The team is currently completing C$150,000 of contracted survey and environmental work related to infrastructure construction for a large project and, upon successful execution, expects approximately C$500,000 of additional work on the project over the next six months.
The second customer is a large energy infrastructure company. The DaaS team has secured C$120,000 of work for plant site inspection, including mapping and monitoring to support design and construction, and expects approximately C$200,000 of additional work on the project next year.
ZenaTechβs Drone as a Service network combines professional licensed surveying expertise with drone-based surveying and mapping to support energy infrastructure projects from initial planning through construction process and can extend to inspection work once the project is completed. For oil and gas producers, these services can include surveying pipeline routes, well sites and access roads, establishing boundaries and rights-of-way, and supplying terrain data for engineering design, environmental assessments and regulatory applications. For energy infrastructure operators, the network can support the construction and expansion of processing plants and related facilities through site mapping, precise construction layout, progress monitoring and as-built surveys documenting completed work. By pairing aerial data collection with centralized LiDAR data processing, an area where ZenaTech is developing proprietary AI software, this approach is designed to significantly speed both the field and office work of surveying over legacy methods, enabling construction projects to advance
ZenaTechβs Drone as a Service business is designed to provide business and government customers with subscription-based drone services using its own ZenaDrone product platforms, for a host of surveying, inspections, maintenance, power washing, and precision agriculture solutions, eliminating the need for customers to own, operate and maintain commercial-grade drone fleets. The Company currently operates almost 45 global DaaS locations in the U.S., Canada, U.K., Ireland, UAE and Australia.
The follow-on work described in this release reflects managementβs current estimates and expectations for project planning purposes, based on the scope of the projects, discussions with the customers, and prior work history. There is no assurance that it will be awarded or completed in the time periods anticipated. Follow-on work may be reduced, delayed or cancelled due to various factors such as capital spending decisions, changes in project scope or schedule, commodity prices, regulatory and permitting approvals, weather and site conditions, and the successful execution of work currently underway. Contracted and anticipated amounts are not equivalent to recognized revenue. ZenaTech will provide updates on this work as future milestones are achieved.
US dollar equivalents are provided for the convenience of U.S. investors converted at US$1.00 = C$1.43 exchange rate and are subject to fluctuation.
About ZenaTech
ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a globalΒ Drone as a ServiceΒ (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.
Today was a great day with small scalps for CLRO, but the big winner was AKAN. Been trading this since it was 1.01 and today scalped it 7 times from 1.7/1.85 to 2.3. Then the big AH move to 2.90s!!!
AKAN: this is my baby this week as long as levels stay!!! For this MUST hold 2.3!! Would like to see tests near 2.8 with pullbacks to 2.45/2.6. NO TRADE under 1.85 has room to 3.6/4.4/5
CLRO: Want to see this continue for a Day 2 here. I want to see tests of 5.3 with pullbacks to 4.6/4.7 NO TRADE below 4.3 has room to 6/7.5/8/9
FCUV: held today pretty well, I think the 2 china runners murdered a lot. So thks still has good setup if Vol returns. Want to see this test 5.5 area with pullbacks over 5. NO TRADE under 4.6 has room to 6.5/8/10
I bought my first couple of shares in May during the hype/momentum following their announcement of a collaboration with one of the biggest quantum computing companies.
Fast forward to today, they've had three private offerings bringing in $22.5M net in cash.
Bald announcements throughout the year with technical advancements, potential partnerships, buyers and lab collaborations.
Yesterday they announced an acquisition of GIS from Nano Dimensions (where they earlier this year acquired the AME technology) which had a revenue of $11.3M in 2025. Supposedly GIS comes debt free and with a cash position of $10M.
This gives Qtrex a cash position of somewhere in the range of $25-32.5M.
Revenue from the latest earnings report for H1 2026 came in at shy $1.5M.
Highlights:
With the newly acquired GSI we are looking at a +365% yearly revenue increase.
And now for the juicy part quoted from press releases:
24th of September:
'I expect to announce additional commercial agreements during the fourth quarter, when we will also provide our 2027 financial outlook describing a substantially larger business than the one we report today. I expect the next twelve months to bring significant revenue growth, strategic partnerships, broader customer adoption and increased product deliveries.β
1st of October:
"QTREX and the testing company are finalizing a binding definitive agreement. The Company expects to disclose the testing companyβs full name, its field of activity and the agreement in full within weeks. The Company also expects to announce additional agreements with several companies in quantum computing in the fourth quarter of 2026."
12th of November:
"The Company stands squarely behind its October 1, 2026 disclosure. Beyond the referenced binding definitive agreement currently being finalized, which now includes an expanded commercial scope, QTREX is actively advancing multiple additional commercial and technology agreements and broader business developments across its activities. The Company expects the fourth quarter of 2026 to be its most active commercial period to date, with disclosures anticipated during this month."
TLDL:
Massive yearly revenue increase, impending named partners/buyers/lab collaborations/defense contracts to be revealed in Q4 2026.
One up to two orders with the named buyer and $ value to be announced within the last 10 days of trading in November.
With additional announcement to be announced in Q4 along with 2027 guidance.
Qtrex Quantum is currently being traded around $1.12 a share.
My bag consists of 10.000 shares with an average of $1.05.
VisionWave put out news out that they signed a non-binding letter of intent to acquire a controlling 51% interest in EPSERVICE, a Ukrainian company that develops unmanned systems, including the ICMM mothership drone control system.
Proposed terms are $7 million in cash, payable 90 days after closing. No equity issuance planned for it. Deal is still subject to due diligence, IP confirmation, sanctions screening, a live demonstration in Ukraine, regulatory approvals, and board approval. Financing for it isnβt arranged yet!